Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Boosts European, Emerging Markets Footprint With $13.6B Nycomed Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

Japan's largest drug maker confirms Nycomed deal, which will double its European sales, jumpstart its emerging markets presence and provide a 30% revenue boost as key drug Actos faces patent expiry.
Advertisement

Related Content

Takeda Emerging Market Strategy Varies From Country To Country
Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion
EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective
EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective
With Nycomed, Takeda Satifies Both Strategic And Financial Objectives
With Nycomed, Takeda Satifies Both Strategic And Financial Objectives
Nycomed US Plans Growth Through Acquisition
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
Takeda’s Millennium Buy Brings In Potential Cancer Blockbuster Velcade
Takeda’s Millennium Buy Brings In Potential Cancer Blockbuster Velcade

Topics

Advertisement
UsernamePublicRestriction

Register

PS072261

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel